Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35670

UPID:
ATP7B_HUMAN

ALTERNATIVE NAMES:
Copper pump 2; Wilson disease-associated protein

ALTERNATIVE UPACC:
P35670; Q16318; Q16319; Q4U3V3; Q59FJ9; Q5T7X7

BACKGROUND:
The protein Copper-transporting ATPase 2, alternatively named Copper pump 2, is pivotal in maintaining copper balance within the body. It ensures the efflux of copper from hepatocytes into the bile, a key process in copper homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in Wilson disease, where copper accumulates due to improper metabolism, understanding the function of Copper-transporting ATPase 2 could open doors to potential therapeutic strategies for managing this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.